Olafsson, Sigurgeir
Rodriguez, Elke http://orcid.org/0000-0003-3692-3950
Lawson, Andrew R. J. http://orcid.org/0000-0003-3592-1005
Abascal, Federico http://orcid.org/0000-0002-6201-1587
Huber, Axel Rosendahl
Suembuel, Melike
Jones, Philip H. http://orcid.org/0000-0002-5904-795X
Gerdes, Sascha
Martincorena, Iñigo http://orcid.org/0000-0003-1122-4416
Weidinger, Stephan
Campbell, Peter J. http://orcid.org/0000-0002-3921-0510
Anderson, Carl A. http://orcid.org/0000-0003-1719-7009
Funding for this research was provided by:
Wellcome Trust (206194, 206194, 108413/A/15/D)
Innovative Medicines Initiative (821511)
Article History
Received: 26 June 2022
Accepted: 20 September 2023
First Online: 26 October 2023
Competing interests
: S.W. has received institutional research grants from Sanofi Deutschland GmbH, LEO Pharma and Pfizer, and performed consultancies and/or lectures for AbbVie, Almirall, Boehringer, Eli Lilly, Galderma, Kymab, Leo Pharma, Regeneron, Sanofi-Genzyme and Novartis. C.A.A. has received consultancy or lecture fees from Genomics plc, BridgeBio and GlaxoSmithKline. Since completing this work, S.O. has become an employee of deCODE Genetics, a subsidiary of Amgen. S.G. has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Affibody AB, Akari Therapeutics Plc, Almirall-Hermal, Amgen, Argenx BV, Aristea Therapeutics, Biogen Idec, Bioskin, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, Hexal AG, Incyte Inc., Janssen-Cilag, Johnson & Johnson, Klinge Pharma, Kymab, Leo Pharma, Medac, MSD, Neubourg Skin Care GmbH, Novartis, Pfizer, Pierre Fabre, Principia Biopharma, Regeneron Pharmaceutical, Sandoz Biopharmaceuticals, Sanofi-Aventis, Trevi Therapeutics and UCB Pharma. M.S. has received speakers’ honoraria and/or participated in clinical trials of the following companies: AbbVie, Affibody AB, Almirall-Hermal, Amgen, Anaptys Bio, Argenx BV, Biogen Idec, Boehringer-Ingelheim, Celgene, Dermira, Eli Lilly, Hexal AG, Incyte Inc., Janssen-Cilag, Kymab, Leo Pharma, Novartis, Pfizer, Regeneron Pharmaceutical, Sanofi-Aventis, Trevi Therapeutics and UCB Pharma. I.M. and P.J.C. are academic cofounders and consultants of Flagship Labs 86. The remaining authors declare no competing interests.